Updated on 2 August 2012
BMS is conducting phase II study of BMS-986094, a nucleotide polymerase inhibitor, for the treatment of hepatitis C
Singapore: Bristol-Myers Squibb (BMS) has suspended study drug administration in an ongoing phase II study of BMS-986094 (formerly known as INX-189), a nucleotide polymerase (NS5B) inhibitor in development for the treatment of hepatitis C. This voluntary action was taken for patient safety based on the emergence of a serious safety issue. The cause of the safety issue and any potential relationship to study drug are yet to be known.
With patient safety as the priority, the company is undertaking an immediate assessment of all patients in the study, and following an evaluation of the patient data, will take appropriate actions.
Survey Box
Subscribe to BioSpectrum Asia digital mag at an attractive price of US $49.99 a year
(Includes all 24 regular & special issues @ fortnightly frequency)
Send this article by email
Australia
China
India
Japan
Korea
Malaysia
New Zealand 
Singapore
Taiwan
Thailand
